Kornimate/medical-research-clean huggingface dataset:
awareness of covid-19 in turkey

Conditions: Healthy

Summary: because covid-19 is a new virus, it is believed that awareness assessment will inform and guide what steps should be taken and which groups should be targeted in terms of controlling the pandemic. according to our hypothesis, covid-19 awareness of individuals in different age groups in the turkish population also varies. there are controlling pratices based on scientific studies made during the outbreak, but there is no certainty as to how much these measures are known by our society. based on these, the aim of our study was to investigate and compare the awareness of new coronavirus (covid-19) in different age groups across turkey.

statistical analysis: in the statistical analysis of the data obtained at the end of the study, spss (statistical package for social sciences / spss 21.0) was analyzed using the statistical program. in the study, arithmetic averages are presented with tables and graphs as mean ± sd (standard deviation) and values indicated by counting in numbers (percent). demographic information of the participants and their responses to the questionnaire questions were evaluated using descriptive statistical analysis method. in the study, independent sample t test was used in parametric data and anova was used in normal non-parametric data. in all analyzes, p \<0,05 was considered statistically significant. sampling: sample size was calculated based on the number of questions asked. accordingly, the number of questions multiplied by the formula of 60 is the lower limit (42\*60=2520). considering the 20% probability of a drop-out and the fact that participants did not want to volunteer, it was decided to take 3150 people to the study. consent will be obtained from the participants through a voluntary information form.

Eligibility criteria:
inclusion criteria: * having at least primary education * being literate in turkish * there is a level of cooperation to understand the evaluations * agree to participate in the study exclusion criteria: * those with audio and visual problems that prevent communication

Keywords: covid-19 pandemic knowledge and awareness adolescent adults
comparisom of liquid nitrogen and vitamin d3 in the treatment of cutaneous warts

Conditions: Cutaneous Warts

Summary: a total of 60 female patients (30 patients in each group) with cutaneious warts diagnosed by a consultant dermatologist on physical examination were included in this study. in group a patients were subjected to liquid nitrogen cryotherapy (-196 0c) while patients in group b were subjected to vitamin d3 (5mg/ml) for 3 sessions at every 3 weeks interval. effectiveness in both groups was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.


Eligibility criteria:
inclusion criteria: * patient of cutaneous warts presented in dermatology department. exclusion criteria: * immunosuppressed patients * chronic skin diseases like eczema or autoimmune disease * diabetes mellitus * cold sensitivity , skin allergies * pregnancy, and lactation * periungual warts
digital health nudging in adolescents with congenital heart disease

Conditions: Congenital Heart Disease

Summary: in adolescents with congenital heart disease physical activity level is reduced which is why promotion to a more active lifestyle with an age-appropriate and modern intervention is needed. in healthy subjects digital health nudging was shown to increase physical activity. however, in adolescents with congenital heart disease such studies have not been conducted yet. in this rct participants receive daily, short smartphone messages with the primary purpose to increase daily physical activity, which is monitored with a "garmin vivofit jr." wearable.


Eligibility criteria:
inclusion criteria: * adolescents aged 12 to 18 years inclusive * presence of a congenital heart defect (must be moderate or complex according to acc criteria) * presence of written informed consent exclusion criteria: * cognitive impairments that inhibit patients from understanding the tasks

Keywords: physical activity promotion digital health nudging
a comparison of manual vs. spontaneous removal of the placenta at cesarean section

Conditions: Pregnancy; Cesarean Section

Summary: the purpose of this study is to determine if there are differences in operative blood loss with manual vs. spontaneous removal of the placenta during cesarean section.

patients undergoing scheduled cesarean deliveries are randomized to manual or spontaneous placental removal.

Eligibility criteria:
inclusion criteria: * all term pregnant women 18 years of age and older undergoing scheduled cesarean delivery at strong memorial hospital. exclusion criteria: * prematurity (\<37 weeks) * preoperative chorioamnionitis * vaginal delivery of fetus * emergency cesarean delivery * patient's ob not agreeable to participating in this study.

Keywords: cesarean delivery placental removal blood loss
cultures a.m.kamme-lindbergh in suspicion of infected tka

Conditions: Total Knee Arthritis; Viral; Infection, Slow Virus

Summary: cultures from total knee arthroplasties, obtained a.m. kamme-lindberg in revision cases.


Eligibility criteria:
inclusion criteria: exclusion criteria:
antimicrobial catheter securement dressings for the prevention of cvc-related bloodstream infections in cancer patients

Conditions: Bloodstream Infection

Summary: in neutropenic cancer patients, catheter-related bloodstream infections may cause severe infections and even death. to assess the prophylactic effect of a chlorhexidine coated catheter securement dressing on the incidence of catheter-related bloodstream infections, this open, randomized trial is being carried out. chg iv tegaderm securement dressing will be randomized in a 1:1 fashion against tegaderm advanced iv securement dressing.


Eligibility criteria:
inclusion criteria: * patients receiving a central venous catheter for chemotherapy of aml or all * patients receiving a central venous catheter for high-dose chemotherapy with consecutive autologous stem cell transplantation or any other condition with an expected duration of chemotherapy-associated neutropenia of at least 5 days and an expected duration of central venous catheter use of at least 10 days * age \>= 18 years exclusion criteria: * condition with an expected duration of chemotherapy-associated neutropenia of at less than 5 days and an expected duration of central venous catheter use of less than 10 days * use of a central venous catheter with antimicrobial coating other than chlorhexidine and/or silver-sulfadiazine * limited venous status, impeding acquisition of peripheral blood cultures in case of febrile neutropenia * patients previously enrolled in the study * tunneled central venous catheters * shaldon catheters * cvc insertion via the v. femoralis * fever (t \> 37.8°c) related to a suspected or confirmed bacterial infection at randomization * known allergic/hypersensitivity reaction to any compounds of the treatment * legal incapacity or limited legal capacity * medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent

Keywords: neutropenia cancer fever central venous catheter infection
monitoring the efficacy of duvalizumab combined with neoadjuvant chemotherapy for ib-iiib nsclc by sequencing of immune receptor repertoire: a prospective, one arm clinical study

Conditions: Ib-IIIb NSCLC

Summary: to observe and evaluate the efficacy and safety of duvalizumab combined with neoadjuvant chemotherapy for ib-iiib nsclc and the relevance with immune receptor repertoire


Eligibility criteria:
inclusion criteria: 1. age: ≥ 18 years old; 2. nsclc confirmed by histopathology; 3. according to the doctor's advice, according to the routine diagnosis and treatment process, lung cancer patients who need radical resection and neoadjuvant therapy before operation; 4. no previous treatment for esophageal cancer, including surgery, chemotherapy, radiotherapy, targeted therapy, hormone or immunotherapy; 5. ecog score was 0 or 1; 6. there was no operative contraindication in preoperative organ function examination; 7. at least 6 months of expected survival 8. the laboratory examination met the following standards: 1. bone marrow function: hemoglobin (hb) ≥ 90g / l; white blood cell count (wbc) ≥ the lower limit of normal value; absolute neutrophil count (anc) ≥ 1.5 × 10\^9/l； platelet count ≥ 90 × 10\^9/l； 2. renal function: cr ≤ unl (upper limit of normal value) × 5, ccr ≥ 55ml / min; 3. liver function: total bilirubin ≤ uln × 1.5； alt and ast ≤ uln × 2.5 (patients with liver metastasis can be relaxed to ≤ 5 \* uln); 4. coagulation function: international normalized ratio of prothrombin time ≤ uln × 5, and partial thromboplastin time was within the normal range; 9. the subjects agreed and voluntarily signed the informed consent exclusion criteria: 1. allergic to the study drug; 2. history of hemorrhagic disease or with hemorrhagic disease 3. liver and kidney dysfunction; 4. patients with uncontrolled diseases (including but not limited to: active infection, symptomatic congestive heart failure; myocardial infarction occurred within 3 months; unstable angina, arrhythmia, etc.); 5. women of childbearing age are unwilling to use contraception; 6. lactating women; 7. for any other reason, the researchers consider it inappropriate to participate in the trial.
vitality acupunch exercise program for sarcopenia older adults

Conditions: Activities of Daily Living; Functional Fitness

Summary: this project was aimed to test the effects of a six-month va program on the activities of daily living (adl) and functional fitness of institutional older adults with sarcopenia.

a cluster-randomized controlled trial was conducted to test the effects of a six-month va program on adl and functional fitness (lung capacity, body flexibility, range of the joint's motion, and muscle endurance) of institutional older adults with sarcopenia. using convenience sampling, 12 long-term care facilities with 114 older adults were recruited, and then cluster-randomized by the facility to a va experimental or a control group. the experimental group received the va program led by certified instructors 3 times per week and 40 minutes per session for six months; the control group continued with their regular daily activities. one pre-test and two post-tests, three months apart, were conducted.

Eligibility criteria:
inclusion criteria: * age ≥ 65 years old * have been living in the facility for at least three months * intact cognitive function with the short portable mental status questionnaire (spmsq) score ≥ 8 * hand-grip strength \< 28 kg for men and \< 18 kg for women * calf circumference \< 34 cm for men and \< 33 cm for women exclusion criteria: * have spinal cord injury * have severe cardiovascular or pulmonary diseases * have musculoskeletal diseases
quantra® system with the qplus® cartridge in double-lung transplantation

Conditions: Lung Diseases; Transplant-Related Disorder

Summary: transfusion in lung transplantation is common, and despite improved techniques and limitations in the use of mechanical circulatory support (mcs), the incidence of massive transfusion has remained stable over the years. the consequences of blood transfusion (blood cells, plasma, platelet concentrates) are deleterious for patients and increase primary graft dysfunction and mortality risk. whole blood viscoelastic testing devices have shown its effectiveness in monitoring coagulation and fibrinolytic function during cardiac surgery, liver transplantation or trauma. so far, few delocalized biology tools have been evaluated in lung transplantation. the main objective of this study is to determine if the use of a transfusion algorithm based on whole blood viscoelastic test with quantra® test reduce transfusion during lung transplantation.


Eligibility criteria:
inclusion criteria: * patients undergoing double-lung transplantation * patient is ≥ 18 years-old * patient is willing to participate, and is willing to consent * patient affiliated to a national health insurance exclusion criteria: * patient is younger than 18 years-old * patient with an indication for non double-lung transplantation * patient under extracorporeal membrane oxygenation in bridge to transplantation * patient with surgery under cardiopulmonary bypass * patient benefiting from a multi-organ transplantation * patient being deprived of liberty or under guardianship * patient refusing to participate

Keywords: resonance sonorheometry viscoelastic testing quantra system lung transplantation
clinical trial to evaluate safety and efficacy of cell therapy in patients with cicatricial conjuntivitis.

Conditions: Chronic Conjunctivitis; Stevens-Johnson Syndrome; Lyell Syndrome; Pemphigoid

Summary: a phase iia, open label, non controlled clinical trial to assess the feasibility and safety of allogeneic adipose-derived mesenchymal stem cells (asc) in the treatment of cicatricial conjunctivitis associated with lyell's syndrome, stevens-johnson's syndrome and mucous membrane pemphigoid with ocular involvement

a multicentre, nationwide clinical trial will be performed. 20 patients fulfilling eligibility criteria will be included in two different dose level cohorts: the first 10 patients included will receive a single cell application and the remainder 10 will be administered 2 cell applications separated by 15 days. the investigational drug consists of locally administered, expanded, allogeneic adipose-derived adult mesenchymal stem cells (ascs), at a dose of 5 million cells per ml (0,5 ml to be infused per quadrant) study cronogram: recruitment is estimated to take 8 months, and follow-up period will be 12 months.

Eligibility criteria:
inclusion criteria: 1. men and women over 18 years of age. 2. diagnosis of ocular pemphigoid in foster stages i-iiciiib (2) or diagnosis of recurrent chronic or episodic inflammation accompanied by cicatricial conjunctivitis of the mucous membranes with ocular involvement after the acute phase of stevens-johnson syndrome or lyell syndrome with insufficient disease control or inaceptable toxicity or impossibility to administer usual care treatments (according to physician or patient criteria) 3. in the case of women of childbearing age, who are willing to use an effective contraceptive method during the period of participation in the study 4. consent to participate and signature of the informed consent exclusion criteria: 1. signs of active infection on the ocular surface. 2. history of neoplasms in the last 5 years. except for epithelial basal or squamous cell carcinoma 3. allergy to local anesthetics 4. patients who have participated in another clinical trial with medication during the 90 days prior to signing the ic 5. medical or psychiatric illness of any kind that, in the opinion of the investigator, may be a reason for exclusion from the study. 6. congenital or acquired immunodeficiencies. 7. major surgery or serious trauma of the subject in the semester prior to signing the ic. 8. pregnant or lactating women. 9. impossibility or refusal to carry out the follow-up required in the study by the patient
safety and efficacy of kanglaite gelcaps in prostate cancer

Conditions: Prostate Cancer

Summary: this research is being done to evaluate the safety and efficacy of the investigational kanglaite gelcap (kltc) on psa in men with prostate cancer when given for twelve months.


Eligibility criteria:
inclusion criteria: * confirmed adenocarcinoma of the prostate * undergone definitive treatment (surgery, surgery with radiation therapy, cryotherapy, radiation therapy or brachytherapy) for the primary prostate tumor with a rising psa * life expectancy greater than 6 months * has eastern cooperative oncology group (ecog) performance status 0, 1, or 2 * use of other dietary/herbal supplements (e.g. saw palmetto, selenium, etc.) has been stable for at least 2 months prior to screening and the patient agrees not to stop or change the dose while participating in the study. * adequate hepatic function with serum bilirubin ≤ 1.5 times the upper institutional limits of normal, alt and ast ≤ 2.5 times the upper institutional limits of normal * adequate renal function with serum creatinine ≤ 1.5 times the upper institutional limits of normal * adequate hematologic function (absolute neutrophil counts ≥ 1,500 mm3 and platelets ≥ 100,000 mm3) * all electrolytes (including potassium, sodium, and serum or ionized calcium) must be within normal limits exclusion criteria: * patients with evidence of metastatic disease would be excluded, except for presence of positive lymph nodes from the surgical pathology. similarly, patients with radiological evidence of lymph nodes \< 2 cm that lack pathological confirmation would be eligible * patients with a psa doubling time of \<6months at screening would be excluded * patients meeting phoenix criteria for biochemical failure (nadir + ≥2ng/ml increase in serum psa) who wish additional conventional therapy * any concurrent malignancy other than adequately treated basal or squamous cell skin cancer or superficial bladder cancer * any psychiatric or other disorders such as dementia that would prohibit the patient from understanding or rendering informed consent or from fully complying with protocol treatment and follow-up * inability to swallow capsules * patients with a known history of gastrointestinal disease, surgery or malabsorption that could potentially impact the absorption of the study drug * patients requiring the use of a feeding tube * receipt of prior chemotherapy
ketamine for acute pain management after trauma

Conditions: Trauma Injury; Pain; Opioid Use

Summary: the purpose of this study is to compare the effectiveness of ketamine drip along with usual care and usual care alone on trauma patients and to longitudinally quantify the pain experience of patients during hospitalization.


Eligibility criteria:
inclusion criteria: * adult trauma patients * admission to shock trauma icu (sticu) or surgical intermediate unit (simu) * randomization within 6 hours of arrival exclusion criteria: * patient not expected to survive * contraindications to ketamine allergy, poorly controlled hypertension, cardiac arrhythmia disorders (including atrial fibrillation), congestive heart failure, unstable coronary artery disease or recent myocardial infarction( mi)(within 6 months), cirrhosis, seizure disorder, and for those patients with unknown medical history - median sternotomy scar, mechanism of injury is fall from standing, 65 years of age or older, any arrhythmia on ekd) * pregnancy * in police custody * history of dementia or movement disorder (i.e. parkinson's)

Keywords: multimodal pain therapy ketamine trauma
ice immersion using virtual reality & augmented reality

Conditions: Pain, Neuropathic; Pain, Acute

Summary: the purpose of this study is to evaluate the effectiveness of different technologies, virtual reality and augmented reality with modifications as passive content, active content, cognitive load modulation, and positive encouragement coaching to increase the pain threshold as assessed by immersing a hand in ice water.


Eligibility criteria:
inclusion criteria: * greater than 18 years of age * english speaking * hearing intact exclusion criteria: * patients who do not consent * currently taking beta blockers or other chronotropic heart medication(s) * have a history of severe motion sickness * currently have nausea * currently experiencing seizures * are clinically unstable * have taken pain medications in the last 12 hours

Keywords: virtual reality augmented reality ice immersion
prone fluid responsiveness in children

Conditions: Pediatric ALL

Summary: in pediatric patients in the prone position, the reliability of pulse pressure variation and stroke volume variation, and pleth variability index to predict fluid responsiveness have not previously been established. perioperatively, in this setting, optimizing fluid management can be challenging, and fluid overload is associated with both intraoperative and postoperative complications. the investigator designed this study to assess the sensitivity and specificity of baseline ppv, svv, and pvi the tidal volume (vt) challenge (vtc) and in predicting fluid responsiveness during elective neurosurgery.


Eligibility criteria:
inclusion criteria: * elective neurosurgery and requiring prone positioning exclusion criteria: * (1) chronic cardiac arrhythmia; (2) depressed left (\<30% of ejection fraction) (3) patients with pulmonary disease
selective reporting for antibiotic susceptibility testing and gps' prescribing of broad-spectrum antibiotics in women with e. coli utis

Conditions: Urinary Tract Infections

Summary: the control of antibiotic resistance requires a reduction in inappropriate prescriptions of broad-spectrum antibiotics (amoxillin-clavulanate (amc), fluoroquinolones (fq), third-generation cephalosporins (c3g)), particularly for urinary tract infections treated in primary care. several studies have reported the positive impact of antibiotic susceptibility testing performed on urine cultures on the appropriate use of antibiotics. the "selective reporting for antibiotic susceptibility testing ", defined as the restriction of the list of antibiotics mentioned in the report according to the antibiotic resistance profile, would allow, according to observational studies, a reduction of 25 to 70% of the initial prescriptions of broad-spectrum antibiotics and a 20% rate of antibiotic de-escalation (=reduction of the antibacterial spectrum of an antibiotic treatment after re-evaluation). the objective is to assess the impact of disseminating a selective reporting for antibiotic susceptibility testing on the dispensing of broad-spectrum antibiotics prescribed by general practitioners (gps) for e. coli positive urine cultures in adult women, compared to the dissemination of a standard antibiotic susceptibility testing.


Eligibility criteria:
inclusion criteria: patients : * women ≥18 years of age, * affiliated with the cpam of loire atlantique (44) or maine et loire (49), * with a urine culture: i) analyzed by labouest, ii) positive for e. coli, and iii) associated with a prescription for antibiotics by a general practitioner in the period 7 days before and 14 days after the antibiotic susceptibility testing. general practitioners : * practicing in primary care loire atlantique (44) and/or maine et loire (49), * having been consulted by at least 100 different patients in the 12 months prior to baseline, * having received at least one urine culture result for a woman ≥18 years of age analyzed by labouest over the 12 months prior to baseline. exclusion criteria: patients : * hospitalized in the period 7 days before and 14 days after antibiotic susceptibility testing (data on antibiotics dispensed in healthcare institutions are not accessible via dcir data), * with reimbursements for antibiotics prescribed by physicians in different practices over the period 7 days before and 14 days after antibiotic susceptibility testing. general practitioners : * with a special practice (acupuncture, allergology, angiology). * not receiving any urine culture results analyzed by a laboratory of the labouest network in the year following the intervention

Keywords: antibiotic therapy general practice primary care public health